West Pharmaceutical Services filed a Worker Adjustment and Retraining Notification on Aug. 2 with the Indiana Department of Workforce Development notifying the agency that it intends to close its Frankfort, IN, contract manufacturing facility in the latter part of this year. “As a result of this closing, virtually all employees employed primarily at the Frankfort plant will be terminated,” said the company in the notification, adding that it expects the Frankfort plant closing to commence after Oct. 1, 2018.
The plant provides custom molding and contract manufacturing services, including complete turnkey assembly, for consumer product applications.
In announcing its Q2 2018 financial results on July 26, West Pharmaceutical reported that its contract manufactured products segment saw organic sales grow 16.9%. This was despite the loss of a consumer product contract manufacturing customer near the start of the year. The growth was fueled by "demand for diagnostic and drug-delivery devices, offsetting declines in the mature consumer-product category," the company said in its report.
West Pharmaceutical reported second quarter net income of $56.1 million compared with $38.8 million, year on year.
Last month, the company announced the official opening of its global center of excellence for advanced manufacturing in Waterford, Ireland. The 20,500-square-meter (approximately five-acre) facility, situated on a 44-acre campus, will produce West's proprietary elastomeric laminate sheeting, which is used to package insulin for use in pen injectors. Additionally, it will offer high-value finishing for components, including stoppers and plungers, produced at other West facilities around the world. The Waterford plant is also one of the company’s first facilities to produce Westar Select components, which help reduce variability and improve quality and safety in drug-delivery and packaging applications.